Annual Scientific Report

More documents

Recommendations

Info

INNOVATION IDIBAPS Organisation chart The IDIBAPS organisation chart is shown below. With a view to ensuring smooth functioning, the research structure of IDIBAPS is supported by the Management and Administration Departments offered by the Fundació Clínic. Ethical Committee in Clinical Research Ethical Committee in Animal Experimentation Governing Board Director Scientific Council Director’s Consultant Council Research Areas Scientific Manager Managing Director Biological aggression and response mechanisnms Respiratory, Cardiovascular and Kidney Bioengineering and Biopathology Scientific Platforms Biobank Flow Cytometry and cell separation Functional Genomics Scientific Management Laboratories Management Knowledge Management Biosecurity Administration Units Research Management Office Liver, Digestive System and Metabolism Medical Imaging Innovation Management Office Clinical and Experimental Neurosciences Bioinformatics International Cooperation Office Oncology and Hematology Accounting & Finance Human Resources Purchases & General Services 12
IDIBAPS Research and Innovation Scientific production Since its creation in 1996, IDIBAPS has shown constant growth of the principal quality indicators of a research centre: The number of scientific publications, theimpact factor, the economic resources, and the contracting of qualified personnel. This section aims to show the evolution of these indicators and other success factors over time, in a graphic and comprehensible manner. Scientific production The number of publications and their impact factor represent one of the most reliable indicators of the competitiveness of a research centre. Both parameters show a clear rising trend in IDIBAPS, and in the year 2010 there have been 846 original publications in scientific journals with an important impact factor. An original paper is taken to be an article contributing new knowledge as a result of experiments performed by investigators of the Institute. In order to be counted as such, the article must have among its signing authors at least one member of the IDIBAPS pertaining to one of the research teams reflected in this Report, with specific mention of IDIBAPS or of the entities with which agreements have been signed. ORIGINALS 2002-2010 The investigators of the IDIBAPS, originating from the different institutions that conform it, are distributed into 5 fields of activity. Each area is divided into different teams that combine in-house research conducted with their own lines of research or in cooperation with other teams. It should be commented that in this Report, and apart from the 5 areas of the IDIBAPS, there is a specific section dedicated to research in Primary Care, Nursing, Pharmacology and Clinical Trials, which also play a very important role in translational research. A good part of the Area of International Health comprises the activity carried out within the setting of the Research Centre in International Health in Barcelona (Centre de Recerca en Salut Internacional de Barcelona) (CRESIB), a centre which thanks to the support of the Catalan government (Generalitat de Catalunya) and other sources of funding has been consolidated due to its solid foundations established over time in IDIBAPS. This implies that the level of growth in number of publications has been attenuated due to the fact that this year it has not been possible to assume as proprietary of IDIBAPS the activities of the mentioned centre, which now takes its own course. Nevertheless, close scientific and administrative ties are maintained with the setting of the IDIBAPS. 900 850 840 846 800 750 736 700 686 650 600 577 550 531 537 500 475 450 452 400 2002 2003 2004 2005 2006 2007 2008 2009 2010 200 160 ORIGINALS 2008-2010 197 210 232 212 221 2008 2009 2010 156 162 168 187 163 163 161 Below is a list of the reported areas, with a graphic representation of the scientific production of each of them - once again considering only the number of original papers. 120 135 138 144 1. Biological aggression and response mechanisms 2. Respiratory, cardiovascular and renal pathobiology and bioengineering 3. Liver, digestive system and metabolism 4. Clinical and experimental neuroscience 5. Oncology and haematology 80 40 0 Area 1 Area 2 Area 3 Area 4 Area 5 13
Page 3 and 4: Annual Scientific Report Rosselló,
Page 5: INDEX Foreword IDIBAPS • Introduc
Page 8 and 9: Presentation IDIBAPS Foreword Intro
Page 10 and 11: Organisation chart Governing Board
Page 14 and 15: It should be mentioned that the sum
Page 16 and 17: Research resources The funding obta
Page 18 and 19: Institució Catalana de Recerca i E
Page 20 and 21: Innovation and transference With th
Page 22 and 23: Spin-off companies The knowledge de
Page 24 and 25: Impact upon clinical practice The f
Page 26 and 27: Title Associated Journal Short Text
Page 28 and 29: IDIBAPS IN FIGURES Surgical innovat
Page 30 and 31: Study of experimental surgery in la
Page 32 and 33: Abreviated Journal Name Original Ar
Page 34 and 35: Abreviated Journal Name Original Ar
Page 36 and 37: INTRODUCTION IDIBAPS Platforms Biob
Page 38 and 39: People Scientific coordinator(s): D
Page 40 and 41: Cytometry and cell sorting www.idib
Page 42 and 43: SOCIETY Functional Genomics The Gen
Page 44 and 45: INTRODUCTION Shared Platforms Prote
Page 46 and 47: SOCIETY DNA Unit (Hospital Clínic)
Page 48 and 49: SOCIETY Electronic Microscopy Unit
Page 50 and 51: NETWORKING Spanish excellence netwo
Page 52 and 53: Spanish Biomedical Research Centre
Page 54 and 55: AIDS Research Network (RIS) www.ret
Page 56 and 57: Networked Biomedical Research Suppo
Page 58 and 59: CIBER IDIBAPS Team Principal invest
Page 60 and 61: CENITS AND CONSOLIDERS CENITs and C
Page 62 and 63:
NoE - Genetic and environmental ris
Page 64 and 65:
TRAINING Research seminars The rese
Page 66 and 67:
Author Title Doctorate thesis reade
Page 68 and 69:
IDIBAPS and society This research c
Page 71 and 72:
Inflammatory joint diseases 72 Syst
Page 73 and 74:
AREA 1 BIOLOGICAL AGGRESSION AND RE
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Respiratory, cardiovascular, renal
Page 105 and 106:
AREA 2 Respiratory, cardiovascular,
Page 107 and 108:
Page 109 and 110:
AREA 2 Respiratory, cardiovascular
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Liver, digestive system metabolism
Page 145 and 146:
AREA 3 Liver, digestive system and
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
AREA 3 LIVER, DIGESTIVE SYSTEM AND
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Clinical and experimental neuroscie
Page 199 and 200:
AREA 4 Clinical and experimental ne
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
oncology and HAEMATOLOGY Biological
Page 249 and 250:
AREA 5 Oncology and haematology Bio
Page 251 and 252:
AREA 5 Oncology and haematology Hum
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
AREA 5 Oncology and haematology Dia
Page 259 and 260:
AREA 5 Oncology and haematology Dia
Page 261 and 262:
AREA 5 Oncology and haematology Mol
Page 263 and 264:
AREA 5 Oncology and haematology Gen
Page 265 and 266:
AREA 5 Oncology and haematology Mel
Page 267 and 268:
AREA 5 Oncology and haematology Mel
Page 269 and 270:
AREA 5 Oncology and haematology Hem
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
AREA 5 Oncology and haematology Phy
Page 281 and 282:
AREA 5 Oncology and haematology Phy
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
AREA 5 Oncology and haematology Cel
Page 293:
AREA 5 Oncology and haematology Cel
Page 296 and 297:
transversal research groups Barcelo
Page 298 and 299:
transversal research groups Clinica
Page 300 and 301:
transversal research groups Clinica
Page 302 and 303:
transversal research groups Transve
Page 304 and 305:
transversal research groups Transve
Page 306 and 307:
transversal research groups Researc
Page 308:
Team leader index A Àlvar Agustí.
show all

Annual Scientific Report

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?